Who we are

Launched in March 2020, COVID-NMA is an international initiative led by the Centre of Research in Epidemiology and StatisticS (METHODS Team) and Cochrane France with key partners the World Health Organization (WHO), Université Paris Cité, Inserm, CNRS, Centre for Evidence-Based Medicine Odense (CEBMO), University of Southern Denmark, Odense University Hospital, Epistemonkos Foundation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, and University of Milan.

This initiative involves a broad multidisciplinary consortium.

Our Vision

Decisions on COVID-19 treatments and preventive interventions are informed through a living Evidence Ecosystem developed by an international collaborative effort.

Our missions

• To inform research planning by producing an up-to-date mapping of trial evidence
• To inform public health and healthcare decisions by producing relevant, accessible, up-to-date, and trustworthy synthesis of high-quality evidence  about the efficacy and safety of interventions for the prevention or treatment of COVID-19
• To improve research value by producing a living monitoring of trial planning, conduct, and reporting  and implementing interventions to transform research practices

Our goals

Our project relies on three main pillars:

1. Performing a living mapping of all registered trial evidence to help funders and researchers planning future trials, 
2. Producing a living systematic review of trial evidence to support healthcare decision making 
3. Assessing trials methodology and transparency to improve future research.

Our values and principles

• Pooling resources and diverse expertise of an international collaboration
• Ensuring flexibility to answer stakeholders’ needs
• Ensuring quality, transparency and reproducibility